Bain Capital Specialty Finance maintained its $0.42 per share regular dividend as Q3 net investment income of $0.43 per share, a 10.3% annualized yield on equity, covered it by 102%; nonaccruals held at 2.2% of portfolio fair value.
BCSF · Bain Capital Specialty Finance, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 64%
- Last earnings
- Nov 10, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Bain Capital Specialty Finance, Inc. declared a fourth fiscal quarter 2026 dividend of $0.42 per share, payable no later than December 29, 2026 to stockholders of record as of December 15, 2026.
Bain Capital Specialty Finance, Inc. invested $121.5 million across 120 portfolio companies and reported a net decrease in investments of $81.6 million for the three months ended September 30, 2026.
Bain Capital Specialty Finance, Inc. will release its financial results for the quarter ended September 30, 2026 on Monday, November 9, 2026 after market close. Management will host a conference call on Tuesday, November 10, 2026 at 10:00 a.m. Eastern Time to discuss the results.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. Q3 net investment income of $0.43 per share covered the regular dividend of $0.42 per share by 102%, credit quality remained healthy with stable nonaccruals, quarter-end liquidity was strong at $962 million, and portfolio yields rose to 11.2% at amortized cost. The main negatives were lower net investment income, net realized and unrealized losses, weak industry deal activity, a larger watchlist, soft ISLP returns, and dividend uncertainty as funding costs reset to higher rates.
- + Net investment income was $0.43 per share, an annualized 10.3% yield on equity that covered the regular dividend by 102%.
- + Credit quality remained healthy and nonaccruals were stable at 2.2% of portfolio fair value.
- + The regular dividend was maintained at $0.42 per share for the fourth quarter, equating to a 10.2% annualized yield on ending Q3 book value.
- + Quarter-end liquidity was strong at $962 million, including $887 million of undrawn revolving credit facility capacity.
- + Portfolio yields increased to 11.2% at amortized cost and 10.7% at fair value.
- + The portfolio is positioned to benefit from higher rates, with a stated sensitivity of approximately $0.01 per share of quarterly earnings for each 100-basis-point base-rate increase.
- − Net investment income declined to $27.7 million, or $0.43 per share, from $28.6 million, or $0.44 per share.
- − The company recorded net realized and unrealized losses of $11 million, or $0.17 per share, for the quarter.
- − Industry deal activity remained weak, and the company deliberately reduced its pace of new originations.
- − Investments rated 3 or 4 increased to 7.4% of portfolio fair value from 5.8% in the prior quarter because of healthcare-company softness.
- − ISLP's trailing four-quarter return on equity was 9%, modestly below the low-double-digit target.
- − The board is evaluating the dividend against a higher-rate funding environment than in 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Aggregate principal amount of debt and equity investments invested since commencing investment o | $10.24B | Since October 13, 2016, through September 30, 2026 | — |
| Annualized NII yield on book value | 10.3% | Q3 2026 | — |
|
|
|||
| Annualized return on book value | 6.2% | Q3 2026 | — |
|
|
|||
| Average notional exposure for interest rate swaps | $700M | the three months ended September 30, 2026 filing | — |
| Average U.S. dollar notional exposure to forward currency exchange contracts | $206.9M | the three months ended September 30, 2026 filing | — |
| Capacity under Sumitomo Credit Facility | $887M | As of September 30, 2026 | — |
| Floating rate debt investments (% of debt investments at fair value) | 94.1% | As of September 30, 2026 | — |
| Fundings in existing companies | $73.6M | Q3 2026 | — |
|
|
|||
| Fundings in new companies | $47.9M | Q3 2026 | — |
|
|
|||
| Gross investment fundings | $121.5M | Q3 2026 | — |
|
|
|||
| Invested, including PIK | $121.5M | the three months ended September 30, 2026 filing | — |
| Investment fundings | $121.5M | three months ended September 30, 2026 | — |
| Investment portfolio fair value | $2.27B | As of September 30, 2026 | — |
| Investments on non-accrual (% of total investment portfolio at amortized cost) | 3.3% | As of September 30, 2026 | — |
| Investments on non-accrual (% of total investment portfolio at fair value) | 2.2% | As of September 30, 2026 | — |
| Net asset value per share | $16.49 | As of September 30, 2026 | — |
| Net investment fundings | -$81.6M | Q3 2026 | — |
|
|
|||
| New portfolio companies invested in (count) | 5 | three months ended September 30, 2026 | — |
|
|
|||
| Portfolio companies (count) | 215 | As of September 30, 2026 | — |
| Portfolio companies invested in (count) | 120 | Q3 2026 | — |
|
|
|||
| Sales and Repayments | $203.1M | Q3 2026 | — |
| Undrawn investment commitments | $435.5M | As of September 30, 2026 | — |
| Weighted average yield on investment portfolio at amortized cost | 11.2% | As of September 30, 2026 | — |
| Weighted average yield on investment portfolio at fair value | 10.7% | As of September 30, 2026 | — |
| Per share net increase in net assets resulting from operations | $0.22 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCSF
this stock
Bain Capital Specialty Finance, Inc.
|
$672.69M | -25.4% | — | 10.8 | 1.8% |
|
BLK
BlackRock, Inc.
|
$178.51B | +2.9% | +16.2% | 25.1 | 1.3% |
|
BN
BROOKFIELD Corp
|
$84.03B | -17.7% | — | — | 1.0% |
|
BX
Blackstone Inc.
|
$83.22B | -28.1% | +9.2% | 24.7 | 2.6% |
|
KKR
KKR & Co. Inc.
|
$78.99B | -30.5% | -11.0% | — | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 17
Bain Capital Specialty Finance, Inc. invested $121.5 million across 120 portfolio companies and reported a net decrease in investments of $81.6 million for the three months ended September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCSF | -6.3% | +3.0% | -22.3% | -3.7% | -25.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.2% | +12.2% | -13.1% | +5.0% | -26.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.